{"product_id":"hmg-75-iu-vial","title":"HMG 75 IU vial","description":"\u003cp data-start=\"75\" data-end=\"406\"\u003e\u003cstrong\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e                                            \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003eFOR HUMAN CONSUMPTION\u003c\/span\u003e\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-start=\"75\" data-end=\"406\"\u003e\u003cstrong data-start=\"92\" data-end=\"113\"\u003eHMG (menotropins)\u003c\/strong\u003e is a \u003cstrong data-start=\"119\" data-end=\"159\"\u003eurinary-derived gonadotropin mixture\u003c\/strong\u003e containing \u003cstrong data-start=\"171\" data-end=\"199\"\u003eboth FSH and LH activity\u003c\/strong\u003e (classically \u003cstrong data-start=\"213\" data-end=\"246\"\u003e75 IU FSH + 75 IU LH per vial\u003c\/strong\u003e in many products). It’s used for \u003cstrong data-start=\"280\" data-end=\"303\"\u003eovulation induction\u003c\/strong\u003e and for \u003cstrong data-start=\"312\" data-end=\"346\"\u003econtrolled ovarian stimulation\u003c\/strong\u003e in ART\/IVF protocols. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp data-start=\"408\" data-end=\"654\"\u003e\u003cstrong data-start=\"408\" data-end=\"424\"\u003eCore concept\u003c\/strong\u003e\u003cbr data-start=\"424\" data-end=\"427\"\u003eFSH primarily drives \u003cstrong data-start=\"448\" data-end=\"483\"\u003efollicle recruitment and growth\u003c\/strong\u003e, while LH activity supports \u003cstrong data-start=\"512\" data-end=\"557\"\u003esteroidogenesis and follicular maturation\u003c\/strong\u003e—useful in selected patients (e.g., certain “low LH” contexts) and in ART stimulation strategies.\u003c\/p\u003e\n\u003cp data-start=\"656\" data-end=\"866\"\u003e\u003cstrong data-start=\"656\" data-end=\"677\"\u003eRegulatory status\u003c\/strong\u003e\u003cbr data-start=\"677\" data-end=\"680\"\u003eMenotropins are \u003cstrong data-start=\"696\" data-end=\"718\"\u003eapproved medicines\u003c\/strong\u003e in many regions (e.g., MENOPUR is widely licensed), but \u003cstrong data-start=\"775\" data-end=\"827\"\u003eindications and labeling vary by country\/product\u003c\/strong\u003e. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-start=\"868\" data-end=\"871\"\u003e\n\u003ch2 data-start=\"873\" data-end=\"965\"\u003eAdditional Benefits \/ Clinical Effects Often Discussed (and what evidence actually shows)\u003c\/h2\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"967\" data-end=\"2298\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"967\" data-end=\"995\"\u003e\n\u003ctr data-start=\"967\" data-end=\"995\"\u003e\n\u003cth data-start=\"967\" data-end=\"977\" data-col-size=\"md\"\u003eBENEFIT\u003c\/th\u003e\n\u003cth data-start=\"977\" data-end=\"995\" data-col-size=\"xl\"\u003eKEY TAKE-AWAYS\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"1006\" data-end=\"2298\"\u003e\n\u003ctr data-start=\"1006\" data-end=\"1209\"\u003e\n\u003ctd data-start=\"1006\" data-end=\"1056\" data-col-size=\"md\"\u003e1) Reliable multifollicular development for ART\u003c\/td\u003e\n\u003ctd data-start=\"1056\" data-end=\"1209\" data-col-size=\"xl\"\u003eHMG is a long-standing backbone for \u003cstrong data-start=\"1094\" data-end=\"1128\"\u003econtrolled ovarian stimulation\u003c\/strong\u003e to obtain multiple oocytes for IVF\/ICSI. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1210\" data-end=\"1426\"\u003e\n\u003ctd data-start=\"1210\" data-end=\"1262\" data-col-size=\"md\"\u003e2) Ovulation induction in anovulatory infertility\u003c\/td\u003e\n\u003ctd data-start=\"1262\" data-end=\"1426\" data-col-size=\"xl\"\u003eIndicated in some settings (e.g., \u003cstrong data-start=\"1298\" data-end=\"1326\"\u003eWHO group II anovulation\u003c\/strong\u003e) when first-line options fail, under specialist monitoring. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1427\" data-end=\"1749\"\u003e\n\u003ctd data-start=\"1427\" data-end=\"1480\" data-col-size=\"md\"\u003e3) Potential differences vs recombinant FSH (rFSH)\u003c\/td\u003e\n\u003ctd data-start=\"1480\" data-end=\"1749\" data-col-size=\"xl\"\u003eEvidence is \u003cstrong data-start=\"1494\" data-end=\"1503\"\u003emixed\u003c\/strong\u003e: some analyses find \u003cstrong data-start=\"1524\" data-end=\"1576\"\u003eno clear live-birth\/ongoing pregnancy difference\u003c\/strong\u003e vs rFSH overall, while others report \u003cstrong data-start=\"1614\" data-end=\"1643\"\u003ehigher clinical pregnancy\u003c\/strong\u003e in certain protocols—results depend on protocol and study design. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"1750\" data-end=\"2065\"\u003e\n\u003ctd data-start=\"1750\" data-end=\"1785\" data-col-size=\"md\"\u003e4) Endocrine profile differences\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-start=\"1785\" data-end=\"2065\"\u003eAdded LH activity can shift \u003cstrong data-start=\"1815\" data-end=\"1846\"\u003eestradiol\/androgen dynamics\u003c\/strong\u003e and follicular steroid environment vs pure FSH stimulation—clinically relevant for some but not universally superior. (Reflected in how protocols are individualized in practice.) \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"2066\" data-end=\"2298\"\u003e\n\u003ctd data-start=\"2066\" data-end=\"2094\" data-col-size=\"md\"\u003e5) Real-world flexibility\u003c\/td\u003e\n\u003ctd data-col-size=\"xl\" data-start=\"2094\" data-end=\"2298\"\u003eIn ART, clinicians may choose HMG to tailor \u003cstrong data-start=\"2140\" data-end=\"2159\"\u003eFSH+LH activity\u003c\/strong\u003e without adding separate LH products—again, not a blanket “better,” but a tool for personalization. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp data-start=\"2300\" data-end=\"2516\"\u003e\u003cstrong data-start=\"2300\" data-end=\"2326\"\u003eEvidence quality note:\u003c\/strong\u003e HMG is “older but established.” The big question in modern literature is usually \u003cstrong data-start=\"2408\" data-end=\"2445\"\u003ecomparative effectiveness vs rFSH\u003c\/strong\u003e (and in which subgroups\/protocols), rather than “does it work at all.”\u003c\/p\u003e\n\u003chr data-start=\"2518\" data-end=\"2521\"\u003e\n\u003ch2 data-start=\"2523\" data-end=\"2558\"\u003e2) Molecular Mechanism of Action\u003c\/h2\u003e\n\u003ch3 data-start=\"2560\" data-end=\"2593\"\u003e2.1 Receptor pharmacodynamics\u003c\/h3\u003e\n\u003cul data-start=\"2594\" data-end=\"3007\"\u003e\n\u003cli data-start=\"2594\" data-end=\"2732\"\u003e\n\u003cp data-start=\"2596\" data-end=\"2732\"\u003e\u003cstrong data-start=\"2596\" data-end=\"2623\"\u003eFSHR (granulosa cells):\u003c\/strong\u003e ↑ follicle recruitment\/growth, ↑ aromatase activity → ↑ estradiol, supports oocyte maturation environment.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"2733\" data-end=\"3007\"\u003e\n\u003cp data-start=\"2735\" data-end=\"3007\"\u003e\u003cstrong data-start=\"2735\" data-end=\"2777\"\u003eLHR (theca\/granulosa in later stages):\u003c\/strong\u003e ↑ androgen substrate production (theca), supports late follicular maturation and luteinization steps (timing depends on protocol).\u003cbr data-start=\"2908\" data-end=\"2911\"\u003eHMG delivers both activities via menotropins preparations. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"3009\" data-end=\"3053\"\u003e2.2 Down-stream biology (high-level map)\u003c\/h3\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"3054\" data-end=\"3562\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"3054\" data-end=\"3096\"\u003e\n\u003ctr data-start=\"3054\" data-end=\"3096\"\u003e\n\u003cth data-start=\"3054\" data-end=\"3064\" data-col-size=\"sm\"\u003ePATHWAY\u003c\/th\u003e\n\u003cth data-start=\"3064\" data-end=\"3085\" data-col-size=\"md\"\u003eFUNCTIONAL OUTCOME\u003c\/th\u003e\n\u003cth data-start=\"3085\" data-end=\"3096\" data-col-size=\"sm\"\u003eCONTEXT\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"3111\" data-end=\"3562\"\u003e\n\u003ctr data-start=\"3111\" data-end=\"3234\"\u003e\n\u003ctd data-start=\"3111\" data-end=\"3138\" data-col-size=\"sm\"\u003eOvarian folliculogenesis\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-start=\"3138\" data-end=\"3182\"\u003emultiple follicles grow under stimulation\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"3182\" data-end=\"3234\"\u003eART cycles \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3235\" data-end=\"3369\"\u003e\n\u003ctd data-start=\"3235\" data-end=\"3253\" data-col-size=\"sm\"\u003eSteroidogenesis\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-start=\"3253\" data-end=\"3297\"\u003eestradiol rises with follicle development\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"3297\" data-end=\"3369\"\u003emonitoring marker + physiology \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"3370\" data-end=\"3562\"\u003e\n\u003ctd data-start=\"3370\" data-end=\"3404\" data-col-size=\"sm\"\u003eOvulation triggering dependency\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-start=\"3404\" data-end=\"3489\"\u003efinal maturation often requires \u003cstrong data-start=\"3438\" data-end=\"3445\"\u003ehCG\u003c\/strong\u003e or equivalent trigger (protocol-dependent)\u003c\/td\u003e\n\u003ctd data-col-size=\"sm\" data-start=\"3489\" data-end=\"3562\"\u003estandard infertility practice \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"3564\" data-end=\"3567\"\u003e\n\u003ch2 data-start=\"3569\" data-end=\"3616\"\u003e3) Pharmacokinetics (PK) (practical framing)\u003c\/h2\u003e\n\u003cul data-start=\"3617\" data-end=\"3950\"\u003e\n\u003cli data-start=\"3617\" data-end=\"3729\"\u003e\n\u003cp data-start=\"3619\" data-end=\"3729\"\u003e\u003cstrong data-start=\"3619\" data-end=\"3629\"\u003eRoute:\u003c\/strong\u003e typically \u003cstrong data-start=\"3640\" data-end=\"3656\"\u003esubcutaneous\u003c\/strong\u003e (some products also allow IM). \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"3730\" data-end=\"3950\"\u003e\n\u003cp data-start=\"3732\" data-end=\"3950\"\u003e\u003cstrong data-start=\"3732\" data-end=\"3769\"\u003ePK varies by product\/purification\u003c\/strong\u003e (HMG is a biologic mixture). Labels focus more on \u003cstrong data-start=\"3820\" data-end=\"3868\"\u003eclinical monitoring (ultrasound + estradiol)\u003c\/strong\u003e than a single “set-and-forget” PK target. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"3952\" data-end=\"3955\"\u003e\n\u003ch2 data-start=\"3957\" data-end=\"4000\"\u003e4) Clinical Evidence (what’s most cited)\u003c\/h2\u003e\n\u003ch3 data-start=\"4002\" data-end=\"4029\"\u003e4.1 ART\/IVF stimulation\u003c\/h3\u003e\n\u003cul data-start=\"4030\" data-end=\"4364\"\u003e\n\u003cli data-start=\"4030\" data-end=\"4364\"\u003e\n\u003cp data-start=\"4032\" data-end=\"4364\"\u003eRCTs and meta-analyses compare \u003cstrong data-start=\"4063\" data-end=\"4078\"\u003eHMG vs rFSH\u003c\/strong\u003e with varied protocols. Some systematic reviews conclude \u003cstrong data-start=\"4135\" data-end=\"4176\"\u003einsufficient evidence of a difference\u003c\/strong\u003e in ongoing pregnancy\/live birth overall; other analyses report \u003cstrong data-start=\"4240\" data-end=\"4269\"\u003ehigher clinical pregnancy\u003c\/strong\u003e in certain long GnRH-agonist down-regulation settings. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-start=\"4366\" data-end=\"4419\"\u003e4.2 Anovulatory infertility \/ ovulation induction\u003c\/h3\u003e\n\u003cul data-start=\"4420\" data-end=\"4608\"\u003e\n\u003cli data-start=\"4420\" data-end=\"4608\"\u003e\n\u003cp data-start=\"4422\" data-end=\"4608\"\u003eUsed under specialist supervision for inducing ovulation in selected patients, with careful monitoring to reduce OHSS and multiple gestation risk. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"4610\" data-end=\"4613\"\u003e\n\u003ch2 data-start=\"4615\" data-end=\"4685\"\u003e5) Emerging clinical interests (where clinicians debate “why HMG?”)\u003c\/h2\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"4686\" data-end=\"5119\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"4686\" data-end=\"4716\"\u003e\n\u003ctr data-start=\"4686\" data-end=\"4716\"\u003e\n\u003cth data-start=\"4686\" data-end=\"4694\" data-col-size=\"sm\"\u003eFIELD\u003c\/th\u003e\n\u003cth data-start=\"4694\" data-end=\"4706\" data-col-size=\"md\"\u003eRATIONALE\u003c\/th\u003e\n\u003cth data-start=\"4706\" data-end=\"4716\" data-col-size=\"md\"\u003eSTATUS\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"4731\" data-end=\"5119\"\u003e\n\u003ctr data-start=\"4731\" data-end=\"4931\"\u003e\n\u003ctd data-start=\"4731\" data-end=\"4763\" data-col-size=\"sm\"\u003e“LH activity” personalization\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-start=\"4763\" data-end=\"4842\"\u003eSome patients may benefit from combined FSH\/LH activity rather than FSH-only\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-start=\"4842\" data-end=\"4931\"\u003eactive clinical debate; not one-size-fits-all \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"4932\" data-end=\"5119\"\u003e\n\u003ctd data-start=\"4932\" data-end=\"4956\" data-col-size=\"sm\"\u003eProtocol optimization\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-start=\"4956\" data-end=\"5048\"\u003eMatching gonadotropin choice to GnRH agonist vs antagonist protocols and patient response\u003c\/td\u003e\n\u003ctd data-col-size=\"md\" data-start=\"5048\" data-end=\"5119\"\u003eongoing comparative studies \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"5121\" data-end=\"5124\"\u003e\n\u003ch2 data-start=\"5126\" data-end=\"5180\"\u003e6) Safety and tolerability (label-level essentials)\u003c\/h2\u003e\n\u003cp data-start=\"5182\" data-end=\"5215\"\u003e\u003cstrong data-start=\"5182\" data-end=\"5215\"\u003eMajor risks (class-defining):\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul data-start=\"5216\" data-end=\"5809\"\u003e\n\u003cli data-start=\"5216\" data-end=\"5455\"\u003e\n\u003cp data-start=\"5218\" data-end=\"5455\"\u003e\u003cstrong data-start=\"5218\" data-end=\"5263\"\u003eOHSS (Ovarian Hyperstimulation Syndrome):\u003c\/strong\u003e can be serious; requires ultrasound\/estradiol monitoring; \u003cstrong data-start=\"5322\" data-end=\"5346\"\u003ewithhold hCG trigger\u003c\/strong\u003e if ovaries are overly enlarged to reduce OHSS risk (per labeling). \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5456\" data-end=\"5571\"\u003e\n\u003cp data-start=\"5458\" data-end=\"5571\"\u003e\u003cstrong data-start=\"5458\" data-end=\"5480\"\u003eMultiple pregnancy\u003c\/strong\u003e risk is increased with gonadotropin stimulation. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5572\" data-end=\"5707\"\u003e\n\u003cp data-start=\"5574\" data-end=\"5707\"\u003e\u003cstrong data-start=\"5574\" data-end=\"5634\"\u003eThromboembolic events \/ serious pulmonary complications:\u003c\/strong\u003e reported (rare but important). \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"5708\" data-end=\"5809\"\u003e\n\u003cp data-start=\"5710\" data-end=\"5809\"\u003e\u003cstrong data-start=\"5710\" data-end=\"5729\"\u003eOvarian torsion\u003c\/strong\u003e: reported after gonadotropin treatment. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-start=\"5811\" data-end=\"6099\"\u003e\u003cstrong data-start=\"5811\" data-end=\"5853\"\u003eContraindications are product-specific\u003c\/strong\u003e, but commonly include: primary ovarian failure (high baseline FSH), certain ovarian cysts not due to PCOS, hormone-dependent tumors, uncontrolled thyroid\/adrenal disorders, and pregnancy (varies by label). \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr data-start=\"6101\" data-end=\"6104\"\u003e\n\u003ch2 data-start=\"6106\" data-end=\"6142\"\u003eComparative “matrix” (conceptual)\u003c\/h2\u003e\n\u003cdiv class=\"TyagGW_tableContainer\"\u003e\n\u003cdiv class=\"group TyagGW_tableWrapper flex flex-col-reverse w-fit\" tabindex=\"-1\"\u003e\n\u003ctable data-start=\"6144\" data-end=\"6685\" class=\"w-fit min-w-(--thread-content-width)\"\u003e\n\u003cthead data-start=\"6144\" data-end=\"6210\"\u003e\n\u003ctr data-start=\"6144\" data-end=\"6210\"\u003e\n\u003cth data-start=\"6144\" data-end=\"6154\" data-col-size=\"sm\"\u003eFEATURE\u003c\/th\u003e\n\u003cth data-start=\"6154\" data-end=\"6191\" data-col-size=\"md\"\u003eHMG (menotropins: FSH+LH activity)\u003c\/th\u003e\n\u003cth data-start=\"6191\" data-end=\"6210\" data-col-size=\"md\"\u003erFSH (FSH-only)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody data-start=\"6225\" data-end=\"6685\"\u003e\n\u003ctr data-start=\"6225\" data-end=\"6377\"\u003e\n\u003ctd data-start=\"6225\" data-end=\"6237\" data-col-size=\"sm\"\u003eMechanism\u003c\/td\u003e\n\u003ctd data-start=\"6237\" data-end=\"6318\" data-col-size=\"md\"\u003ecombined FSH + LH activity in one prep \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003ctd data-start=\"6318\" data-end=\"6377\" data-col-size=\"md\"\u003eFSH-only stimulation (with\/without added LH separately)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6378\" data-end=\"6563\"\u003e\n\u003ctd data-start=\"6378\" data-end=\"6404\" data-col-size=\"sm\"\u003eEfficacy (IVF outcomes)\u003c\/td\u003e\n\u003ctd data-start=\"6404\" data-end=\"6504\" data-col-size=\"md\"\u003emixed evidence vs rFSH; not consistently superior overall \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003ctd data-start=\"6504\" data-end=\"6563\" data-col-size=\"md\"\u003emixed comparative evidence; depends on protocol\/patient\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-start=\"6564\" data-end=\"6685\"\u003e\n\u003ctd data-start=\"6564\" data-end=\"6583\" data-col-size=\"sm\"\u003eMonitoring needs\u003c\/td\u003e\n\u003ctd data-start=\"6583\" data-end=\"6667\" data-col-size=\"md\"\u003ehigh (US + E2) due to OHSS\/multiples risk \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\n\u003c\/td\u003e\n\u003ctd data-start=\"6667\" data-end=\"6685\" data-col-size=\"md\"\u003esimilarly high\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr data-start=\"6687\" data-end=\"6690\"\u003e\n\u003ch2 data-start=\"6692\" data-end=\"6735\"\u003e7) Regulatory \/ supply notes (practical)\u003c\/h2\u003e\n\u003cul data-start=\"6736\" data-end=\"6953\"\u003e\n\u003cli data-start=\"6736\" data-end=\"6953\"\u003e\n\u003cp data-start=\"6738\" data-end=\"6953\"\u003e\u003cstrong data-start=\"6738\" data-end=\"6749\"\u003eMenopur\u003c\/strong\u003e has had \u003cstrong data-start=\"6758\" data-end=\"6806\"\u003equality-defect–related supply communications\u003c\/strong\u003e in Europe (example: EMA DHPC notice), reminding that sourcing and batch quality can matter with biologics. \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"6955\" data-end=\"6958\"\u003e\n\u003ch2 data-start=\"6960\" data-end=\"7020\"\u003e8) Future directions (what would sharpen decision-making)\u003c\/h2\u003e\n\u003cul data-start=\"7021\" data-end=\"7315\"\u003e\n\u003cli data-start=\"7021\" data-end=\"7119\"\u003e\n\u003cp data-start=\"7023\" data-end=\"7119\"\u003eBetter \u003cstrong data-start=\"7030\" data-end=\"7057\"\u003esubgroup identification\u003c\/strong\u003e (who truly benefits from built-in LH activity vs FSH-only).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7120\" data-end=\"7315\"\u003e\n\u003cp data-start=\"7122\" data-end=\"7315\"\u003eHead-to-head trials using \u003cstrong data-start=\"7148\" data-end=\"7162\"\u003elive birth\u003c\/strong\u003e as primary endpoint with modern protocols and standardized dosing rules (a recurring recommendation in reviews). \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr data-start=\"7317\" data-end=\"7320\"\u003e\n\u003ch3 data-start=\"7322\" data-end=\"7345\"\u003eSelected references\u003c\/h3\u003e\n\u003cul data-start=\"7346\" data-end=\"7715\"\u003e\n\u003cli data-start=\"7346\" data-end=\"7438\"\u003e\n\u003cp data-start=\"7348\" data-end=\"7438\"\u003eMENOPUR FDA label \/ description and composition: \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7439\" data-end=\"7517\"\u003e\n\u003cp data-start=\"7441\" data-end=\"7517\"\u003eUK SmPC (composition\/indications): \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7518\" data-end=\"7624\"\u003e\n\u003cp data-start=\"7520\" data-end=\"7624\"\u003eComparative effectiveness reviews\/meta-analyses (HMG vs rFSH): \u003cspan class=\"\" data-state=\"closed\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli data-start=\"7625\" data-end=\"7715\"\u003e\n\u003cp data-start=\"7627\" data-end=\"7715\"\u003eEMA DHPC (supply\/quality communication example):\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":52684843745618,"sku":null,"price":32.5,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/HMG_75IU.png?v=1770834815","url":"https:\/\/sciencepeptideslab.com\/products\/hmg-75-iu-vial","provider":"Science Peptides Lab","version":"1.0","type":"link"}